PILOT
831175
XINGANJIANG
873167
Beijing Highlander Digital Technology
300065
Hangzhou Gaoxin Materials Technology
300478
Shijihengtong Technology
301428
CN Stock MarketDetailed Quotes
605199 Hainan Huluwa Pharmaceutical Group
- 18.07
- -0.41-2.22%
Not Open Feb 17 15:00 CST
7.23BMarket Cap64.08P/E (TTM)
18.42High17.70Low172.70KlotVolume18.42Open18.48Pre Close311.08MTurnover4.32%Turnover Ratio67.93P/E (Static)400.11MShares25.1652wk High6.26P/B7.23BFloat Cap9.0952wk Low20.33Limit Up400.11MShs Float49.61Historical High16.63Limit Down3.90%Amplitude5.96Historical Low0.13Dividend TTM18.01Avg Price92.09KlotAsk0.69%Div YieldTTM100Lot Size69.87KlotBid
Hainan Huluwa Pharmaceutical Group News
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on providing guarantees for wholly-owned subsidiaries
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the receipt of GMP compliance test results by its wholly-owned subsidiary
Huluwa: Announcement on Abnormal Stock Trading Fluctuations and Risk Alerts for Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement on abnormal stock trading fluctuations and risk alerts of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Huluwa: Hainan Huluwa Pharmaceutical Group Co., Ltd. Stock Trading Risk Warning Notice
Hainan Huluwa Pharmaceutical Group Co., Ltd. Stock Trading Risk Warning Notice
Hainan Huluwa Pharmaceutical Group Co., Ltd. Stock Trading Risk Warning Notice
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Legal Opinion of Beijing Guofeng Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the progress of capital increase for wholly-owned subsidiaries through debt-for-share swaps
Meeting materials of the 2024 Second Extraordinary General Meeting of Shareholders of Hainan Huluwa Pharmaceutical Group Co., Ltd.
Notice of Hainan Huluwa Pharmaceutical Group Co., Ltd. on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on changing some fund-raising investment projects
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on by-election of independent directors
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the receipt of GMP compliance test results by its wholly-owned subsidiary
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on the resignation of an independent director at the end of their term of office
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on increasing the capital of wholly-owned subsidiaries through debt-for-share swaps
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on providing guarantees for wholly-owned subsidiaries
Announcement of Hainan Huluwa Pharmaceutical Group Co., Ltd. on providing guarantees for wholly-owned subsidiaries
Hainan Huluwa Pharmaceutical Group Co., Ltd. received the Shanghai Stock Exchange\'s “Decision on Termination of the Review of Hainan Huluwa Pharmaceutical Group Co., Ltd.\'s Issuance of Convertible Corporate Bonds to Unspecified Targets”
